Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aqua Bio Technology Share Issue/Capital Change 2019

Oct 9, 2019

3535_rns_2019-10-09_fce62a4f-827b-4057-a3a1-4de7c41dba0f.html

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

AQUA BIO TECHNOLOGY ASA - REGISTRATION OF SHARE CAPITAL INCREASE

AQUA BIO TECHNOLOGY ASA - REGISTRATION OF SHARE CAPITAL INCREASE

Reference is made to the stock exchange notice of Aqua Bio Technology ASA (the

"Company") dated 30 August 2019, regarding expiry of the exercise period for the

warrants issued by the Company pursuant to the general meeting's resolution on

7 January 2019 (the "Warrants").

At the expiry of the exercise period for the Warrants, the Company had received

notice of exercise of 3,609,277 Warrants, which imply that the Company has

issued 3,609,277 new shares, each with a par value of NOK 2.50, and that the

share capital of the Company is increased with NOK 9,023,192.50.

The share capital increase pertaining to the exercise of the Warrants has now

been registered in the Norwegian Register of Business Enterprises. The new share

capital of the Company is NOK 38,420,427.50 divided by 15,368,171 shares, each

with a par value of NOK 2.50. The new shares will be admitted to trading on Oslo

Axess as soon as possible under ticker "ABT".

For further information, please contact Espen Kvale, acting CEO, telephone

+47 916 28 092 or [email protected]

Aqua Bio Technology (ABT) is developing and commercializing sustainable

biotechnology for use in skin care products. ABT's cosmetics ingredients are

highly effective and they provide the cosmetics industry with natural

alternatives to traditional ingredients. ABT is also marketing and distributing

natural skin care products developed by partners towards consumers and

professional users. Aqua Bio Technology is listed on the Axess market of the

Oslo Stock Exchange.

This information is subject to the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.